Background. Adenovirus infections are associated with significant rates of morbidity and mortality among children after bone marrow transplantation (BMT). Many transplantation units use molecular virological methods, such as polymerase chain reaction (PCR), for surveillance for adenovirus infection and give preemptive antiviral therapy to children with evidence of disseminated adenovirus infection. This treatment strategy has never been evaluated in clinical trials.
Adenovirus is an important cause of morbidity and mortality among allogeneic bone marrow transplant (BMT) recipients. Children are at much higher risk of acquiring adenovirus infection than are adults [1, 2] , with up to 37% becoming positive for adenovirus in the posttransplantation period [3] . Mortality rates as high as 60% have been reported for invasive disease [4] . Studies of both adults and children have suggested that those who receive T cell-depleted transplants have the greatest risk of developing adenovirus infection [5, 6] .
Several recent studies have used molecular virological methods, such as PCR, for the diagnosis of adenovirus infection [5, 6] . They have identified rates of infection that are much higher than those reported previously, and PCR is now being increasingly used for routine surveillance for adenovirus in clinical practice. Many centers, including our own, have developed treatment protocols that are based on surveillance for adenovirus by PCR, whereby children whose blood samples have positive PCR results (or who have other evidence of disseminated adenovirus infection) receive preemptive antiviral therapy with either intravenous ribavirin or cidofovir. In addition, quantification of viremia is now possible with the use of real-time PCR, and it has been suggested that children who are viremic are at greatest risk of dying from disseminated adenovirus infection [5] . Treatment strategies based on identification of virus in blood by PCR and quantification of virus load with real-time PCR have never been validated by clinical trials. The aim of this study was to determine the incidence among and clinical spectrum of adenovirus infection in children who had undergone hemopoi-etic allogeneic stem cell transplantation before the introduction of routine surveillance for adenovirus, with use of PCR for diagnosis.
PATIENTS AND METHODS
Thirty pediatric patients underwent hemopoietic allogeneic stem cell transplantation at the Royal London Hospital between May 1998 and June 2002. Two children received transplants because of nonmalignant conditions (severe aplastic anemia in one and congenital sideroblastic anemia in the other). The others had a variety of malignant conditions, including acute lymphoblastic leukemia, acute myeloid leukemia, and nonHodgkin lymphoma. Ex vivo T cell depletion, with either alemtuzumab and/or rabbit antithymocyte globulin, was used during the pretransplantation conditioning for 9 patients. These 9 children received grafts from either matched unrelated donors or haploidentical family donors. One child who received a transplant from a matched sibling donor was given antithymocyte globulin because of severe graft-versus-host disease. Four children were excluded from the study because no stored blood was available for testing.
Whole blood samples, which were stored at Ϫ70ЊC at the Virology Department of St. Bartholemew's Hospital (London), were tested for adenovirus DNA by PCR. Samples had been collected weekly from each child after transplantation to screen for new or reactivation of cytomegalovirus infection. A total of 273 whole blood samples obtained from 26 children were available for testing. The mean number of samples obtained from each child was 11 (range, 3-49 samples). Clinical notes, laboratory parameters, and virology records were reviewed for each child.
Qualitative PCR. DNA was extracted by use of the QIAmd DNA Blood Minikit protocol (Qiagen) according to the manufacturer's recommendations. The following PCR primers were used: Hex 1, 5 -ATGACTTTTGAGGTGGATCCCATGGA-3 ; and Hex 2, 5 -GCCGAGAAGGGCGTGCGCAGGTA-3 . The product size was 134 bp.
Adenovirus DNA sequences were derived from the highly conserved hexon genes and have previously been shown to be highly sensitive for detecting adenovirus DNA in different tissue samples [7, 8] . Reference strains of adenovirus obtained from previous patients were used as positive controls. Each sample that tested positive was retested by the same method. Only those patients who had positive test results on both occasions were identified as having adenovirus infection. Statistical comparisons were done with the x 2 test. Quantitative PCR. Virus load in positive samples was quantitated by use of a real-time PCR assay developed in our laboratory, based on the TaqMan method described elsewhere [9] . The primers that were used are shown in table 1.
RESULTS

Adenovirus infections.
Patients who had positive test results for adenovirus are described in table 2. Eleven (42%) of 26 patients had stool, bronchoalveolar lavage, or eye swab specimens that were culture-positive and blood samples that were PCR-positive for adenovirus after BMT. Four patients (patients 2, 4, 6, and 9) were identified as having stool specimens (obtained at the time of infection) that were culture-positive for adenovirus, and of these, 2 (patients 2 and 6) died from probable adenovirus disease. We were unable to detect adenovirus in the blood of the other 2 patients who had adenovirus in stool specimens. One patient had reactivation of cytomegalovirus infection and was treated with ganciclovir and cidofovir (patient 2), and the other had severe gastroenteropathy (proven on biopsy) attributed to adenovirus (patient 9), but no blood was available from either patient for PCR testing for adenovirus.
Seven children had adenovirus infection identified only by retrospective PCR testing. Two children were asymptomatic and had been discharged home. The other 5 patients all had symptoms and signs that, in retrospect, could have been attributed to adenovirus infection.
Of the children who had symptomatic infection, adenovirus was isolated a mean of 17 days after BMT (range, 4 days before to 27 days after BMT). One child developed infection at day 60 after BMT, 20 days treatment involving T cell depletion with antithymocyte globulin because of severe graft-versus-host disease. The 2 children who died of disseminated adenovirus disease developed infection within 2 weeks after BMT. One had a stool sample obtained 4 days before BMT that tested positive for adenovirus, but adenovirus was not identified by culture until after BMT was performed. The 2 children who were asymptomatic developed infection later than did those with symptoms (on days 50 and 270 after BMT).
Adenovirus infection was significantly more likely to occur in children who had received a T cell-depleted BMT. Seven (70%) of 10 who received alemtuzumab or antithymocyte globulin developed infection, compared with only 4 (25%) of 16 who received unmanipulated grafts ( ). Of the children P p .04 who received T cell-depleted transplants, the 2 who died had very low absolute lymphocyte counts ( lympho-9 ! 0.35 ϫ 10 cytes/mL for both) at the time adenovirus was initially detected.
Quantitation of adenovirus. Blood for quantitative PCR was obtained from 9 patients. Table 2 lists the maximum number of adenovirus DNA copies for each patient. There was no direct correlation between virus load and severity of symptoms. However, 5 children (including those who were asymptomatic) had virus loads of copies/mL, and each cleared the 4 ! 2 ϫ 10 virus within 2 weeks after infection. Three children had virus loads of 110 5 copies/mL, and 2 of these children were viremic for 14 weeks (figure 1). 
DISCUSSION
We identified a group of children with adenovirus infections after BMT who were not identified at the time of their infection and who survived without antiviral treatment. The children in this study underwent BMT before the use of PCR for diagnosis of adenovirus infection became routine. They were tested for infection only if there was a clinical suspicion of adenovirus infection. A significant proportion of the children in our study had evidence of adenovirus infection only on the basis of retrospective testing by PCR. The spectrum of clinical presentations was varied and included several children who, in retrospect, had symptoms and signs consistent with adenovirus infection. The symptoms and signs of adenovirus infection may be difficult to differentiate from those of other viral infections or other conditions, such as graft-versus-host disease. Children may not be specifically tested for adenovirus if other causes for their symptoms are suspected. For this reason, we believe that surveillance with PCR is the optimum way to detect adenovirus infection in children who have undergone BMT. None of the antiviral treatments currently available have proven efficacy for treating adenovirus infection [1] , and both ribavirin and cidofovir have significant associated toxicity [1] [2] [3] [4] [5] . However, given the extremely poor outcomes for patients with disseminated infection [6] , our current treatment policy is to ensure that children with viremia receive antiviral therapy. The retrospective nature of this study has allowed us to identify severely immunocompromised children with adenovirus infection who were not treated with antiviral therapy. Although adenovirus viremia has been associated with disseminated disease and high mortality, our study demonstrates that adenovirus viremia is common after BMT and that a significant number of children may clear the virus without treatment. Seven of our patients had adenovirus viremia and were able to clear the virus from their blood without antiviral therapy. Five of these had virus loads of copies/mL and cleared the 6 ! 2 ϫ 10 virus within 2 weeks after infection.
Since the introduction of routine PCR-based surveillance for adenovirus infection, the reported rates of infection have increased significantly [1, 6, 7] . Some of this increase may be because of the sensitivity of PCR, which can detect infection in patients who previously may not have been identified by means of culture for virus. PCR surveillance for viremia may allow detection of virus in blood before the patient develops symptoms. Given the lack of evidence for the efficacy of an- tiviral therapy, it may be appropriate to use early detection of infection and frequent quantitation of virus load to monitor selected children in the early stages of infection without drug therapy. Our study suggests that, for some children with adenovirus infection after BMT, potentially toxic antiviral therapy is unnecessary [10] . We found that a high proportion (42%) of our children had adenovirus infection. This is slightly higher than other studies have demonstrated by use of PCR for adenovirus surveillance. Samarasinghe et al. [3] found 37% of their patients to be positive for adenovirus, whereas more recently, Lion et al. [5] identified 27% with adenovirus infection. We cannot exclude the possibility that PCR contamination caused false-positive results. However, all but 1 of our children had adenovirus detected in consecutive weekly samples, suggesting sustained viremia. In addition, our method of retesting samples and confirming the results with real-time PCR decreases the likelihood of false-positive results.
We were able to confirm the findings of others [3, 5, 6 ] that adenovirus infection is more likely to occur in patients who have received T cell-depleted BMTs. A statistically significant difference in the incidence of adenovirus infection was demonstrated between children who received T cell-depleted and those who received unmanipulated BMTs, even though the number of children studied was small. In addition, we were able to demonstrate that, for symptomatic children, adenovirus was detectable in the blood within 30 days after transplantation. Both children who died of presumed adenovirus disease became viremic within 2 weeks after BMT and had low absolute lymphocyte counts, suggesting that their degree of immunosuppression may have contributed to the severity of disease.
We were not able to demonstrate a direct correlation between clinical presentation, disease severity, and quantification of virus in the blood in this small group of patients. However, we did not have a complete set of blood samples for 1 child who died of adenovirus disease after transfer to another hospital. It is interesting to note that the 2 asymptomatic children had relatively low levels of viremia and cleared the virus within 2 weeks after infection. For 2 children with high virus loads, we observed that there was a gradual increase in the number of copies of virus over several weeks before the load reached a peak (figure 1). Prospective surveillance for adenovirus infection is likely to have identified these children early, when they had low levels of viremia and possibly before they became symptomatic. Early detection of adenovirus viremia would allow the possibility of preemptive antiviral therapy, which some authors have suggested may improve the outcome of adenovirus infection in these children [3] .
The results of this study reinforce the importance of adenovirus as a potential pathogen in severely immunocompromised children. The routine use of molecular virological methods in clinical practice is likely to increase the rate of detection of adenovirus infections in children after BMT. Our results suggest that not all children with adenovirus viremia will develop symptoms or require antiviral therapy, and clinicians should be aware that some immunocompromised children are able to clear the virus spontaneously. Additional research is needed to identify optimal monitoring and treatment strategies for patients undergoing BMT who have adenovirus infection and to determine the role that quantification of virus has for predicting adenovirus disease.
